Navigation Links
Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Date:1/26/2009

easing sales and profits. He is a seasoned professional who has successfully managed multiple new product launches," said Daniel M. Bradbury, President and Chief Executive Officer, Amylin Pharmaceuticals. "Vince will add significant value to Amylin as we look to grow BYETTA and SYMLIN revenue and finalize our commercial plans for exenatide once weekly. As an integral part of our executive committee, we look forward to the strategic contributions Vince will make, as well as the fresh perspective he will bring during this exciting time."

Mr. Mihalik will oversee marketing and sales for Amylin's two marketed products, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, as well as the launch and commercialization of exenatide once weekly, Amylin's lead development compound. He will become a member of Amylin's executive committee.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin. The Company's actual results could differ materially from those discussed in this press release due to a number of risks and uncertainties, including risks that BYETTA and SYMLIN, and the revenues we generate from these products, may be affected by competition, unexpected new dat
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
2. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
3. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
4. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
8. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
9. Amylin and Lilly Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 2008 at 9:00 a.m. Eastern ... ... ALSE ) today reports operational and,financial results for the quarter ended ... http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the progress we ...
... Named Contract Manufacturer of Choice, Based on Its ... Based on its recent,analysis of the pharmaceutical ... BioPharma Solutions (BPS) with the 2008 North,American Frost ... Award at,the 2008 Excellence in Healthcare Innovation Awards ...
... Novavax uses strategies to create vaccines for avian flu ... genetically-engineered virus-like particles (VLPs), ROCKVILLE, Md., ... today that its strategy for treating avian flu,through genetically-engineered ... at Cleveland Clinic 6th Annual Medical Innovation,Summit., Novavax, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... soot or black carbon turns out to be ... to carbon dioxide, according to a four-year assessment by an ... soot particles in smoke and smog, contributes about twice as ... 2007 Intergovernmental Panel on Climate Change. "We were surprised at ...
... bacteria and tree, How the protein transport machinery ... Physcomitrella patens is an evolutionary intermediate stage ... have studied how the protein transport system of ... in the chloroplasts of higher plants. They explored ...
... span eight countries from France to Slovenia and harbour an ... found nowhere else. They are widely considered to be ... biodiversity in Europe. But the Alps are not just ... of up to 14 million people and the destination for ...
Cached Biology News:International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3How the protein transport machinery in the chloroplasts of higher plants developed 2How the protein transport machinery in the chloroplasts of higher plants developed 3In search of the big questions: Conserving the European Alps 2In search of the big questions: Conserving the European Alps 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: